Market is expected to reach $6.9 billion in 2022 due to its evolving role in companion diagnostics, finds Frost & Sullivan
SANTA CLARA, Calif., Aug. 2, 2018 /PRNewswire/ -- Clinical laboratories' intensifying demand for a robust solution to manage data and the declining availability of skilled pathologists is making a strong case for
"Another important growth strategy in the tissue diagnostics market is developing end-to-end integrated workflow solutions that can position the company as a one-stop shop," said Supratik Paul, Senior Industry Analyst, Transformational Health. "Collaborations with anatomic pathology LIS (APLIS) vendors and partnerships in emerging markets with instrument distributors will allow them to gain an end-to-end tissue diagnostics portfolio and efficient supply chain, respectively."
Frost & Sullivan's recent analysis, Global Tissue Diagnostics Market, Forecast to 2022, highlights key market participants, customer segments, and restraining factors such as liquid biopsy and reimbursement cuts. It segments the market by pre-analytical staining, advanced staining, and APLIS across the United States, Western Europe, Asia-Pacific, and Rest of the World. This market is expected to register a CAGR of 7.9% from $4.7 billion in 2017 to $6.9 billion in 2022 due to its evolving role in companion diagnostics and use of automation.
For further information on this analysis, please visit: http://frost.ly/2ns
Regional trends in the tissue diagnostic market include:
Some of the top companies with innovation-led growth strategies include Roche (VENTANA HE 600), Sakura (Tissue-Tek Genie), Leica Biosystems (BOND RNAscope on BOND-III), Xifin (XIFIN AP Labs), NovoPath (NovoPath AP Software), 3DHISTECH (iSacs), and MIPS (DaVinci).
"Collaborations will be one of the key growth drivers in the tissue diagnostics market, especially partnerships with companion diagnostics (CDx) vendors," noted Paul. "These partnerships will enable contract tissue diagnostic vendors to strengthen their next-generation sequencing (NGS)-based assay capabilities across emerging CDx-enabling technologies such as NGS-based multiplex tests, single molecule real-time (SMRT) sequencing, digital pathology, and quantitative IHC."
Global Tissue Diagnostics Market, Forecast to 2022 is part of Frost & Sullivan's global Life Sciences Growth Partnership Service program.
About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Global Tissue Diagnostics Market, Forecast to 2022K25A-55
Contact:Mariana FernandezT: +1 210 348 10 12T: +54 11 4778 3540E: Mariana.Fernandez@frost.com
View original content:http://www.prnewswire.com/news-releases/tissue-diagnostics-companies-focus-on-automation-and-partnerships-to-expand-revenues-300691341.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!